
Dipeptidyl peptidase‐4 inhibitors (DPP4Is) may mitigate hypoglycemia‐mediated declines in cognitive and physical functioning compared to sulfonylureas (SUs), yet comparative studies are unavailable among older adults, especially nursing home (NH) residents. We evaluated the effects of DPP4Is versus SUs on cognitive and physical functioning among NH residents. This new‐user cohort study included long‐stay NH residents aged ≥65 years from the 2007‐2010 national US Minimum Data Set (MDS) clinical assessments and linked Medicare claims. We measured cognitive decline from the validated 6‐point MDS Cognitive Performance Scale, functional decline from the validated 28‐point MDS Activities of Daily Living scale...
Like
Save
Share